Table 1.
Characteristics of CMV- and EBV-specific cells and EC50 values of Gαs-coupled receptor agonists
Total CMV-specific cellsEarly differentiated CMV-specific cellsIntermediate differentiated CMV-specific cellsLate differentiated CMV-specific cellsTotal EBV-specific cells
% of A2-NLV+ or A2-GLC+ ± SEM 100 32.8 ± 4.0 32.9 ± 5.1 30.6 ± 5.8 100 
% mICAM-1+ ± SEM 83.0 ± 3.7 77.6 ± 4.6 83.5 ± 3.6 85.9 ± 5.0 30.3 ± 8.8 
MFI of mICAM-1+ ± SEM 12,730 ± 1,904 8,459 ± 1,081 13,596 ± 1,796* 15,423 ± 3,198* 2,325 ± 988 
EC50 of isoproterenol, M 1.4 × 10−10 1.27 × 10−10 1.47 × 10−10 1.58 × 10−10 9.9 × 10−11 
EC50 of epinephrine, M 3.9 × 10−10 3.20 × 10−10 4.15 × 10−10* 3.94 × 10−10* 2.5 × 10−10 
EC50 of norepinephrine, M 3.2 × 10−8 3.22 × 10−8 3.04 × 10−8 3.62 × 10−8 1.2 × 10−8 
EC50 of PGE2, pg/ml 931 504 1,135* 1,073* 303 
EC50 of PGD2, pg/ml 797 606 737 810 952 
Total CMV-specific cellsEarly differentiated CMV-specific cellsIntermediate differentiated CMV-specific cellsLate differentiated CMV-specific cellsTotal EBV-specific cells
% of A2-NLV+ or A2-GLC+ ± SEM 100 32.8 ± 4.0 32.9 ± 5.1 30.6 ± 5.8 100 
% mICAM-1+ ± SEM 83.0 ± 3.7 77.6 ± 4.6 83.5 ± 3.6 85.9 ± 5.0 30.3 ± 8.8 
MFI of mICAM-1+ ± SEM 12,730 ± 1,904 8,459 ± 1,081 13,596 ± 1,796* 15,423 ± 3,198* 2,325 ± 988 
EC50 of isoproterenol, M 1.4 × 10−10 1.27 × 10−10 1.47 × 10−10 1.58 × 10−10 9.9 × 10−11 
EC50 of epinephrine, M 3.9 × 10−10 3.20 × 10−10 4.15 × 10−10* 3.94 × 10−10* 2.5 × 10−10 
EC50 of norepinephrine, M 3.2 × 10−8 3.22 × 10−8 3.04 × 10−8 3.62 × 10−8 1.2 × 10−8 
EC50 of PGE2, pg/ml 931 504 1,135* 1,073* 303 
EC50 of PGD2, pg/ml 797 606 737 810 952 

*, P ≤ 0.05 for comparisons between early versus intermediate or late differentiated CMV-specific T cells.

[ViewLarge]
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal